CARBAMAZEPINE | A078115 | TARO PHARMACEUTICAL INDUSTRIES LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc. FDA-2019-P-3545 · 7 docket documents Axinn, on behalf of Zydus Pharmaceuticals (USA) Inc., filed this citizen petition under Section 505 of the FD&C Act requesting that FDA require pending and approved abbreviated new drug applications for Carbamazepine Extended Release Tablets referencing Tegretol XR to comply with the March 2015 prod | 505(q) | 2019-07-26 | DeniedUnverified summary | Zydus Pharmaceuticals (USA) Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.6133
per ea
Lowest NADAC/Unit
$0.1989
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 51672412501CARBAMAZEPINE ER 400 MG TABLET | $0.6133 | EA | Generic | — | 2026-08-19 |
| 51672412401CARBAMAZEPINE ER 200 MG TABLET | $0.3776 | EA | Generic | — | 2026-08-19 |
| 51672412301CARBAMAZEPINE ER 100 MG TABLET | $0.1989 | EA | Generic | — | 2026-08-19 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.